Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 23062-06-8
2. Fasedienol
3. Aloradine
4. 4,16-androstadien-3-beta-ol
5. 4,16-androstadien-3beta-ol
6. Dtw1nj7ijh
7. (3s,8s,9s,10r,13r,14s)-10,13-dimethyl-2,3,6,7,8,9,10,11,12,13,14,15-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol
8. Androsta-4,16-dien-3-ol, (3b)-
9. (3s,8s,9s,10r,13r,14s)-10,13-dimethyl-2,3,6,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-ol
10. (3as,3bs,7s,9ar,9bs,11ar)-9a,11a-dimethyl-3h,3ah,3bh,4h,5h,7h,8h,9h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-7-ol
11. 4-androstadienol
12. Unii-dtw1nj7ijh
13. Fasedienol [inn]
14. Aloradine [who-dd]
15. Ph94b
16. Androsta-4,16-dien-3beta-ol
17. Schembl4075431
18. Androsta-4,16-diene-3beta-ol
19. Dtxsid901032322
20. (3b)-androsta-4,16-dien-3-ol
21. Yaa06206
22. Mfcd00271236
23. Zinc34031047
24. Akos028109412
25. As-60043
26. Androsta-4,16-dien-3-ol, (3.beta.)-
27. Hy-145567
28. Cs-0376082
29. Q20707597
| Molecular Weight | 272.4 g/mol |
|---|---|
| Molecular Formula | C19H28O |
| XLogP3 | 4.6 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 1 |
| Rotatable Bond Count | 0 |
| Exact Mass | 272.214015512 g/mol |
| Monoisotopic Mass | 272.214015512 g/mol |
| Topological Polar Surface Area | 20.2 Ų |
| Heavy Atom Count | 20 |
| Formal Charge | 0 |
| Complexity | 476 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 6 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Intended for the acute treatment of social phobia.
Vomeropherin compounds are directly delivered to the nasal passages using either a metered nasal spray or a metered nasal aerosol. By virtue of the chemoreceptors location in the nasal passages, direct connections to the hypothalamus and limbic system and the ability of our compounds to act locally, vomeropherins do not need to achieve systemic absorption and distribution. This provides a significant therapeutic advantage over traditional therapeutics targeted at the hypothalamus and limbic system that require access to systemic circulation and must cross the blood-brain barrier followed by uptake into the brain to exert effects.
Absorption
Absorbed following nasal administration.
There is little information available on the mechanism of action of vomeropherins. These compounds are delivered to the nasal passages and bind to chemoreceptors that in turn affect the hypothalamus and the limbic system.
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Fasedienol manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Fasedienol, including repackagers and relabelers. The FDA regulates Fasedienol manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Fasedienol API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Fasedienol supplier is an individual or a company that provides Fasedienol active pharmaceutical ingredient (API) or Fasedienol finished formulations upon request. The Fasedienol suppliers may include Fasedienol API manufacturers, exporters, distributors and traders.
Fasedienol Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Fasedienol GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Fasedienol GMP manufacturer or Fasedienol GMP API supplier for your needs.
A Fasedienol CoA (Certificate of Analysis) is a formal document that attests to Fasedienol's compliance with Fasedienol specifications and serves as a tool for batch-level quality control.
Fasedienol CoA mostly includes findings from lab analyses of a specific batch. For each Fasedienol CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Fasedienol may be tested according to a variety of international standards, such as European Pharmacopoeia (Fasedienol EP), Fasedienol JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Fasedienol USP).
LOOKING FOR A SUPPLIER?
